EyeWorld reports from this years AAO the following:
Ionized drug demonstrates rapid onset and long-lasting action in patients with dry eye
SAN FRANCISCO — A topical dexamethasone administration that is delivered to the eye by a novel drug delivery system involving ionization of drug particles by electrical current rapidly decreases clinical signs and symptoms related to dry eye, according to a poster presented here.
In a study, patients who received either a low-dose or high-dose application of EGP-437 (dexamethasone phosphate ophthalmic solution optimized for iontophoresis, EyeGate Pharma and Ora) reported a significant decrease in ocular discomfort after exposure to a controlled adverse environmental (CAE) challenge, which exacerbates dry eye signs and symptoms, compared with placebo, according to a poster presented at the joint meeting of the American Academy of Ophthalmology and Pan-American Association of Ophthalmology.
As well, study drug patients had a significant decrease in inferior region fluorescein staining at their seventh visit compared with baseline, which "demonstrates that two EGP-437 treatments over 3 weeks, which include three CAE visits, may aid healing in this region," according to the poster.
No comments:
Post a Comment